Developer docs
API playgroundTry for free, no card

Search company profiles

Phenox

Full company profile

uuid000aeal

Namestring
Phenox
Legal namestring
phenox GmbH
Websiteurl
phenox.net
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Phenox GmbH is a privately held German medical device company headquartered in Bochum, founded in 2005, that develops and commercializes neurovascular devices for the treatment of ischemic stroke and cerebral aneurysms. The company sells three core product families — the pRESET line of stent retriever thrombectomy devices (including pRESET, pRESET LITE, and pRESET LUX variants) for mechanical clot removal; the pEGASUS self-expanding open-cell stent system for wide-neck aneurysms, dissections, and intracranial stenoses; and the Avenir Coil System, which is manufactured by Wallaby Medical and distributed by phenox — all carrying CE Mark approval (CE 0297 and CE 2797) for European and international markets but not approved for sale in the United States. Differentiated proprietary technology includes HPC (Hydrophilic Polymer Coating), an antithrombogenic coating now supported by the COATING Randomized Controlled Trial demonstrating safety with Single Antiplatelet Therapy, and the pRESET device's helical slit and dual-type cell design for first-pass thrombectomy success.

Phenox operates a direct enterprise sales model targeting hospitals and ambulatory surgical centers with interventional neuroradiology departments, with revenue generated through hardware device sales. The company maintains clinical evidence leadership via the PROST trial published in JAMA Neurology (2024) and the COATING trial published in JNIS (2025), and has received non-dilutive R&D funding from European and German government programs (EFRE NRW, EU, BMBF, Bundes-ESF). Commercial operations appear commercially linked to Wallaby Medical through shared "WallabyPhenox" branding and the wallabyphenox.com marketing domain, suggesting a deeper commercial relationship than a standalone distributor arrangement, though the precise ownership structure is not publicly disclosed. The company has 101–250 employees and is led by CEO James Lago, founder Hermann Monstadt, and CFO Attila Kravecz, with only one known institutional venture funding event (SHS Capital, 2010).

Short descriptiontext

Phenox GmbH is a Bochum, Germany-based private medical device company that develops and sells CE-marked neurovascular devices — including the pRESET thrombectomy, pEGASUS stent, and Avenir coil systems — to hospitals and ambulatory surgical centers for ischemic stroke and aneurysm treatment in markets outside the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBochum, Germany
HQ citystring
Bochum
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurovascular medical devices, thrombectomy devices, aneurysm treatment systems, ischemic stroke intervention, flow diversion stents
Industry1 code
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neurovascular Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

phenox generates revenue through the sale of neurovascular medical devices including the pRESET thrombectomy devices, pEGASUS stent systems, and distributed Avenir coil systems. Products are sold directly to hospitals and healthcare facilities with CE Mark approval for European and international markets.

phenox.net
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1pRESET
Description

Thrombectomy device for ischemic stroke treatment, including pRESET 4-20, 5-40, 6-30 for proximal treatment and pRESET LITE 3-20, 4-20 for distal treatment, and pRESET LUX with visible HPC coating.

phenox.net
+2 more records
Core offering1 text field

Phenox develops, manufactures, and distributes CE Mark-certified neurovascular medical devices for the treatment of cerebral aneurysms and ischemic stroke. Its core product portfolio includes the pRESET family of stent retriever thrombectomy devices (pRESET, pRESET LITE, pRESET LUX) for mechanical clot removal, the pEGASUS self-expanding stent system for wide-neck aneurysms and intracranial stenoses, and the Avenir Coil System (manufactured by Wallaby Medical) for aneurysm embolization. Devices are sold through direct sales relationships with hospitals and ambulatory surgical centers internationally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • HPC-coated flow diverters proven safe for use with Single Antiplatelet Therapy (SAPT) based on COATING RCT 1-month safety results published in JNIS 2025
+1 more record
Product overview1 text field

Phenox is a medical device company specializing in neurovascular treatments for ischemic stroke and aneurysm treatment. The product portfolio centers on three core device families: the pRESET line of stent retriever thrombectomy devices (including pRESET, pRESET LITE, and pRESET LUX variants) for mechanical clot removal in acute ischemic stroke; the pEGASUS Stent System for wide-neck aneurysm, dissection, and intracranial stenosis treatment; and the Avenir Coil System (manufactured by Wallaby Medical) for aneurysm embolization. These devices are offered with optional HPC (Hydrophilic Polymer Coating) technology for enhanced thrombogenicity profiles. All products carry CE Mark certification and are not approved for sale in the United States.

Product and service5 records
1pRESET Thrombectomy Device
CategoryThrombectomy Device
Description

Stent retriever thrombectomy device for mechanical clot removal in acute ischemic stroke treatment. Features helical slit design with dual type cell architecture for deep clot integration and flexibility in tortuous anatomies. Available in sizes 4-20, 5-40, 6-30, and 6-50 for large thrombus load in proximal treatment locations. CE Mark certified (CE 0297).

2pRESET LITE Thrombectomy Device
CategoryThrombectomy Device
Description

Distal treatment variant of the pRESET thrombectomy device, designed for smaller vessels with sizes 3-20 and 4-20 for treating distal thrombus locations in acute ischemic stroke. CE Mark certified (CE 0297).

3pRESET LUX Thrombectomy Device
CategoryThrombectomy Device
Description

pRESET variant featuring full visibility through NAC (Noble Alloy Coating) on the full length of the device, designed for first-pass success in proximal thrombus treatment. CE Mark certified (CE 0297).

4pEGASUS Stent System
CategoryIntracranial Stent System
Description

Self-expanding, open-cell stent designed for treatment of wide-neck aneurysms, dissections, and intracranial stenoses. Features optimal adaptation to different vessel configurations for vessels from 2.5mm to 4.5mm, and is available with optional antithrombogenic HPC (Hydrophilic Polymer Coating) technology.

5Avenir Coil System
CategoryEmbolization Coil System
Description

Coil embolization system for aneurysm treatment manufactured by Wallaby Medical and distributed by phenox GmbH. Available in 18 Complex Framing, 10 Complex Finishing, 10 Helical Finishing, and 10 Helical Filling configurations with ultra-soft 0.0013 inch primary wire for enhanced conformability and packing density, featuring an instant detachment mechanism. CE Mark certified (CE 2797).

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or Integration
Description

Wallaby Medical manufactures the Avenir Coil System (CE 2797), which is distributed by phenox GmbH. The Avenir is available in 18 Complex Framing, 10 Complex Finishing, 10 Helical Finishing, and 10 Helical Filling versions. This partnership allows phenox to offer a comprehensive coil embolization solution as part of their neurovascular treatment portfolio.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Rapid Medical is an Israeli neurovascular device company developing stent retrievers, distal access catheters, and flow diverters for stroke and aneurysm treatment. It competes head-to-head with Phenox across the neurointerventional procedure workflow in CE Mark and select global markets.

TypeDirect peer
Description

Penumbra is a US-based neurovascular and vascular thrombectomy company that directly competes with Phenox's pRESET stent retriever in mechanical thrombectomy for acute ischemic stroke. Both companies serve hospitals and interventional neuroradiology departments with hardware-based clot retrieval solutions.

TypeRegional player
Description

Balt is a French-based neurovascular and interventional neuroradiology device manufacturer with a broad portfolio of coils, stents, and flow diverters. It is a comparable European regional player serving similar CE Mark markets to Phenox.

TypeBroad incumbent
Description

Stryker's Neurovascular division (formed via the Concentric Medical and Codman Neuro acquisitions) offers stent retrievers, aspiration catheters, and coils. It is a broad incumbent competitor to Phenox in stroke intervention and aneurysm treatment.

5MIVI Neuroscience
TypeEmerging player
Description

MIVI Neuroscience develops innovative stroke treatment devices including aspiration catheters and stent retrievers. As a smaller, focused neurovascular player, it competes with Phenox's pRESET line in the mechanical thrombectomy segment.

TypeDirect peer
Description

Wallaby Medical manufactures the Avenir Coil System distributed by Phenox and appears closely affiliated with Phenox under the wallabyphenox.com brand. Both companies serve the neurovascular aneurysm and stroke markets with complementary coil and stent retriever technologies.

TypeDirect peer
Description

Acandis is a German neurovascular device company specializing in intracranial stents, flow diverters, and coil systems for aneurysm treatment. It is a direct regional competitor to Phenox in Europe, with comparable CE Mark product portfolios.

8MicroPort Scientific (Neurovascular)
TypeBroad incumbent
Description

MicroPort's neurovascular division, formed through acquisition of Stryker's Neurovascular business, competes with Phenox in flow diversion and stent retriever markets globally. It serves as a broad incumbent with FDA-approved products across major geographies.

TypeBroad incumbent
Description

Cerenovus is Johnson & Johnson's neurovascular division, offering stent retrievers, coils, flow diverters, and embolization products. As a broad incumbent, it competes with Phenox across the full neurointerventional procedure workflow with significant R&D and commercial resources.

TypeBroad incumbent
Description

Medtronic, through its acquisition of Covidien and the Solitaire stent retriever franchise, is a global incumbent in the neurovascular devices market. It competes with Phenox across thrombectomy, flow diversion, and aneurysm treatment with FDA-approved products and broad hospital coverage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Phenox

Neurovascular Medical Devicesphenox.net

Phenox GmbH is a Bochum, Germany-based private medical device company that develops and sells CE-marked neurovascular devices — including the pRESET thrombectomy, pEGASUS stent, and Avenir coil systems — to hospitals and ambulatory surgical centers for ischemic stroke and aneurysm treatment in markets outside the United States.

What Phenox does

Phenox GmbH is a privately held German medical device company headquartered in Bochum, founded in 2005, that develops and commercializes neurovascular devices for the treatment of ischemic stroke and cerebral aneurysms. The company sells three core product families — the pRESET line of stent retriever thrombectomy devices (including pRESET, pRESET LITE, and pRESET LUX variants) for mechanical clot removal; the pEGASUS self-expanding open-cell stent system for wide-neck aneurysms, dissections, and intracranial stenoses; and the Avenir Coil System, which is manufactured by Wallaby Medical and distributed by phenox — all carrying CE Mark approval (CE 0297 and CE 2797) for European and international markets but not approved for sale in the United States. Differentiated proprietary technology includes HPC (Hydrophilic Polymer Coating), an antithrombogenic coating now supported by the COATING Randomized Controlled Trial demonstrating safety with Single Antiplatelet Therapy, and the pRESET device's helical slit and dual-type cell design for first-pass thrombectomy success.

Phenox operates a direct enterprise sales model targeting hospitals and ambulatory surgical centers with interventional neuroradiology departments, with revenue generated through hardware device sales. The company maintains clinical evidence leadership via the PROST trial published in JAMA Neurology (2024) and the COATING trial published in JNIS (2025), and has received non-dilutive R&D funding from European and German government programs (EFRE NRW, EU, BMBF, Bundes-ESF). Commercial operations appear commercially linked to Wallaby Medical through shared "WallabyPhenox" branding and the wallabyphenox.com marketing domain, suggesting a deeper commercial relationship than a standalone distributor arrangement, though the precise ownership structure is not publicly disclosed. The company has 101–250 employees and is led by CEO James Lago, founder Hermann Monstadt, and CFO Attila Kravecz, with only one known institutional venture funding event (SHS Capital, 2010).

Phenox firmographics

Firmographics
Name
Phenox
Legal name
phenox GmbH
Website
https://phenox.net
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
101–250 employees
Short description
Phenox GmbH is a Bochum, Germany-based private medical device company that develops and sells CE-marked neurovascular devices — including the pRESET thrombectomy, pEGASUS stent, and Avenir coil systems — to hospitals and ambulatory surgical centers for ischemic stroke and aneurysm treatment in markets outside the United States.
Ownership category
akta.pro rank

Phenox industry classification

Industry
Product category
Neurovascular Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Neurovascular medical devices
  • Thrombectomy devices
  • Aneurysm treatment systems
  • Ischemic stroke intervention
  • Flow diversion stents

Where Phenox is headquartered

Location

Headquarters

HQ city
Bochum
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Phenox business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: phenox generates revenue through the sale of neurovascular medical devices including the pRESET thrombectomy devices, pEGASUS stent systems, and distributed Avenir coil systems. Products are sold directly to hospitals and healthcare facilities with CE Mark approval for European and international markets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Phenox product offering

Product offering

Core offering

Phenox develops, manufactures, and distributes CE Mark-certified neurovascular medical devices for the treatment of cerebral aneurysms and ischemic stroke. Its core product portfolio includes the pRESET family of stent retriever thrombectomy devices (pRESET, pRESET LITE, pRESET LUX) for mechanical clot removal, the pEGASUS self-expanding stent system for wide-neck aneurysms and intracranial stenoses, and the Avenir Coil System (manufactured by Wallaby Medical) for aneurysm embolization. Devices are sold through direct sales relationships with hospitals and ambulatory surgical centers internationally.

Product overview

Phenox is a medical device company specializing in neurovascular treatments for ischemic stroke and aneurysm treatment. The product portfolio centers on three core device families: the pRESET line of stent retriever thrombectomy devices (including pRESET, pRESET LITE, and pRESET LUX variants) for mechanical clot removal in acute ischemic stroke; the pEGASUS Stent System for wide-neck aneurysm, dissection, and intracranial stenosis treatment; and the Avenir Coil System (manufactured by Wallaby Medical) for aneurysm embolization. These devices are offered with optional HPC (Hydrophilic Polymer Coating) technology for enhanced thrombogenicity profiles. All products carry CE Mark certification and are not approved for sale in the United States.

Differentiator

Problem solved

Functional benefit

Brands

  • pRESET: Thrombectomy device for ischemic stroke treatment, including pRESET 4-20, 5-40, 6-30 for proximal treatment and pRESET LITE 3-20, 4-20 for distal treatment, and pRESET LUX with visible HPC coating.
  • pEGASUS
  • Avenir Wallaby

Products and services

  • pRESET Thrombectomy Device Stent retriever thrombectomy device for mechanical clot removal in acute ischemic stroke treatment. Features helical slit design with dual type cell architecture for deep clot integration and flexibility in tortuous anatomies. Available in sizes 4-20, 5-40, 6-30, and 6-50 for large thrombus load in proximal treatment locations. CE Mark certified (CE 0297).
  • pRESET LITE Thrombectomy Device Distal treatment variant of the pRESET thrombectomy device, designed for smaller vessels with sizes 3-20 and 4-20 for treating distal thrombus locations in acute ischemic stroke. CE Mark certified (CE 0297).
  • pRESET LUX Thrombectomy Device pRESET variant featuring full visibility through NAC (Noble Alloy Coating) on the full length of the device, designed for first-pass success in proximal thrombus treatment. CE Mark certified (CE 0297).
  • pEGASUS Stent System Self-expanding, open-cell stent designed for treatment of wide-neck aneurysms, dissections, and intracranial stenoses. Features optimal adaptation to different vessel configurations for vessels from 2.5mm to 4.5mm, and is available with optional antithrombogenic HPC (Hydrophilic Polymer Coating) technology.
  • Avenir Coil System Coil embolization system for aneurysm treatment manufactured by Wallaby Medical and distributed by phenox GmbH. Available in 18 Complex Framing, 10 Complex Finishing, 10 Helical Finishing, and 10 Helical Filling configurations with ultra-soft 0.0013 inch primary wire for enhanced conformability and packing density, featuring an instant detachment mechanism. CE Mark certified (CE 2797).

Quantifiable outcome

  • HPC-coated flow diverters proven safe for use with Single Antiplatelet Therapy (SAPT) based on COATING RCT 1-month safety results published in JNIS 2025
  • +1 more outcomes

Companies that use Phenox

Customer profile

Segments1 record

Ideal customer profiles1 record

Phenox technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Phenox partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Wallaby MedicalcoreTechnology or IntegrationWallaby Medical manufactures the Avenir Coil System (CE 2797), which is distributed by phenox GmbH. The Avenir is available in 18 Complex Framing, 10 Complex Finishing, 10 Helical Finishing, and 10 Helical Filling versions. This partnership allows phenox to offer a comprehensive coil embolization solution as part of their neurovascular treatment portfolio.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Phenox competitors and assessment

Company assessment

Direct peers

  • Rapid Medical: Rapid Medical is an Israeli neurovascular device company developing stent retrievers, distal access catheters, and flow diverters for stroke and aneurysm treatment. It competes head-to-head with Phenox across the neurointerventional procedure workflow in CE Mark and select global markets.
  • Penumbra: Penumbra is a US-based neurovascular and vascular thrombectomy company that directly competes with Phenox's pRESET stent retriever in mechanical thrombectomy for acute ischemic stroke. Both companies serve hospitals and interventional neuroradiology departments with hardware-based clot retrieval solutions.
  • Wallaby Medical: Wallaby Medical manufactures the Avenir Coil System distributed by Phenox and appears closely affiliated with Phenox under the wallabyphenox.com brand. Both companies serve the neurovascular aneurysm and stroke markets with complementary coil and stent retriever technologies.
  • Acandis: Acandis is a German neurovascular device company specializing in intracranial stents, flow diverters, and coil systems for aneurysm treatment. It is a direct regional competitor to Phenox in Europe, with comparable CE Mark product portfolios.

Regional players

  • Balt: Balt is a French-based neurovascular and interventional neuroradiology device manufacturer with a broad portfolio of coils, stents, and flow diverters. It is a comparable European regional player serving similar CE Mark markets to Phenox.

Broad incumbents

  • Stryker (Neurovascular): Stryker's Neurovascular division (formed via the Concentric Medical and Codman Neuro acquisitions) offers stent retrievers, aspiration catheters, and coils. It is a broad incumbent competitor to Phenox in stroke intervention and aneurysm treatment.
  • MicroPort Scientific (Neurovascular): MicroPort's neurovascular division, formed through acquisition of Stryker's Neurovascular business, competes with Phenox in flow diversion and stent retriever markets globally. It serves as a broad incumbent with FDA-approved products across major geographies.
  • Johnson & Johnson (Cerenovus): Cerenovus is Johnson & Johnson's neurovascular division, offering stent retrievers, coils, flow diverters, and embolization products. As a broad incumbent, it competes with Phenox across the full neurointerventional procedure workflow with significant R&D and commercial resources.
  • Medtronic (Neurovascular): Medtronic, through its acquisition of Covidien and the Solitaire stent retriever franchise, is a global incumbent in the neurovascular devices market. It competes with Phenox across thrombectomy, flow diversion, and aneurysm treatment with FDA-approved products and broad hospital coverage.

Emerging players

  • MIVI Neuroscience: MIVI Neuroscience develops innovative stroke treatment devices including aspiration catheters and stent retrievers. As a smaller, focused neurovascular player, it competes with Phenox's pRESET line in the mechanical thrombectomy segment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Phenox social profiles

Digital presence

Phenox compliance and trust

Trust signal

Compliance3 records

Phenox financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Phenox leadership team

Management profile

Number of profiles

Profiles3 records

Phenox funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Phenox M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phenox

What does Phenox do?

Phenox develops, manufactures, and distributes CE Mark-certified neurovascular medical devices for the treatment of cerebral aneurysms and ischemic stroke. Its core product portfolio includes the pRESET family of stent retriever thrombectomy devices (pRESET, pRESET LITE, pRESET LUX) for mechanical clot removal, the pEGASUS self-expanding stent system for wide-neck aneurysms and intracranial stenoses, and the Avenir Coil System (manufactured by Wallaby Medical) for aneurysm embolization. Devices are sold through direct sales relationships with hospitals and ambulatory surgical centers internationally.

Is Phenox a public or private company?

Phenox is a private company. It is classified as unknown and is currently operating.

When was Phenox founded?

Phenox was founded in 2005. It employs 101 to 250 people.

Where is Phenox based?

Phenox is headquartered in Bochum, Germany, in the Europe region.

How does Phenox make money?

One revenue line is on record: medical Device Sales.

Who are Phenox's main competitors?

Direct peers on record are Rapid Medical, Penumbra, Wallaby Medical and Acandis. Balt is listed as a regional player. Broad incumbents are Stryker (Neurovascular), MicroPort Scientific (Neurovascular), Johnson & Johnson (Cerenovus) and Medtronic (Neurovascular). MIVI Neuroscience is listed as an emerging player.

Does Phenox have an API?

No public API is recorded for Phenox.

What industry is Phenox in?

Phenox's product category is Neurovascular Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireWallaby Acquires German Neurovascular Leader Phenox to Accelerate Global ExpansionWallaby Medical has completed the acquisition of German neurovascular company phenox GmbH and its subsidiary femtos for approximately EUR 500 million. This transaction, which received all necessary regulatory approvals, combines the product portfolios and geographic reach of both entities to create a global leader in stroke treatment technologies. The deal is driven by strong growth opportunities and aims to provide a comprehensive spectrum of interventional neurovascular solutions across major international markets.PR NewswireMechanical Thrombectomy Devices Market worth $ 2.27 Billion by 2030 - Exclusive Report by InsightAce AnalyticInsightAce Analytic Pvt. Ltd. has published a market assessment report estimating the global mechanical thrombectomy devices market will grow from US$ 1.26 billion in 2021 to US$ 2.27 billion by 2030, representing a compound annual growth rate of 6.9%. The report identifies rising cardiovascular diseases, technological advancements in medical devices, and increasing demand for minimally invasive procedures as primary market drivers, while also noting constraints including a lack of trained surgeons and device-related complications. Key industry developments include Boston Scientific Corporation's acquisition of Devoro Medical Inc. in September 2021, along with multiple product launches from Imperative Care, phenox, Vascular Medcure, and Medtronic, with North America and Asia-Pacific projected as the fastest-growing regional markets.